Drug Profile
Research programme: wound and pain therapeutics - National Pharmaceuticals
Alternative Names: GLB333Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Globe Laboratories
- Developer National Pharmaceuticals Corp
- Class Cytokines; Growth factors; Interleukins; Recombinant proteins
- Mechanism of Action Cytokine inhibitors; Growth modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain; Wounds